<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02581176</url>
  </required_header>
  <id_info>
    <org_study_id>CAP</org_study_id>
    <nct_id>NCT02581176</nct_id>
  </id_info>
  <brief_title>Apixaban as Treatment of Venous Thrombosis in Patients With Cancer: The CAP Study</brief_title>
  <acronym>CAP</acronym>
  <official_title>Apixaban as Treatment of Venous Thrombosis in Patients With Cancer: The CAP Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Akershus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Akershus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a single-arm, phase IV trial, of apixaban as treatment of venous thrombosis in
      patients with cancer. The current standard treatment of venous thrombosis in cancer patients
      is subcutaneous injections with low molecular weight heparin. During the last 5 years several
      new direct acting oral anticoagulants have been tested out as treatment of venous thrombosis.
      But very few cancer patients were included in the phase III clinical trials of the direct
      acting oral anticoagulants. Thus, there is a lack of information on how cancer patients with
      venous thrombosis will respond to treatment with direct acting oral anticoagulants. The
      current study will investigate the direct acting oral anticoagulant apixaban in cancer
      patients with venous thrombosis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrent objectively confirmed venous thrombosis or death related to venous thrombosis</measure>
    <time_frame>6 months after inclusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Major or clinically relevant non-major bleeding</measure>
    <time_frame>6 months after inclusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>6 months after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>24 months after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent objectively confirmed venous thrombosis or death related to venous thrombosis</measure>
    <time_frame>24 months after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major or clinically relevant non-major bleeding</measure>
    <time_frame>24 months after inclusion</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Neoplasms</condition>
  <condition>Venous Thrombosis</condition>
  <arm_group>
    <arm_group_label>Apixaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apixaban 10 mg two times daily for 1 week, then apixaban 5mg two times daily for 6 months, then apixaban 2.5 mg two times daily for as long as the treating physician finds it necessary.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <arm_group_label>Apixaban</arm_group_label>
    <other_name>Eliquis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A diagnosis of cancer, other than basal-cell or squamous-cell carcinoma of the skin,
             within six months before enrollment. Any treatment for cancer within the previous six
             months, or recurrent or metastatic cancer.

          -  Objectively verified venous thrombosis

          -  Informed consent

        Exclusion Criteria:

          -  Anticoagulant therapy prior to trial entry for &gt; 96 hours

          -  Severe thrombocytopenia (platelets &lt;50·109/L)

          -  Severe renal failure - creatinine clearance &lt;30 ml/min

          -  The patients will be treated with catheter based thrombolysis for deep venous
             thrombosis or systemic thrombolysis for severe pulmonary embolism

          -  Pregnancy or breastfeeding.

          -  Childbearing potential without proper contraceptive measures

          -  Drug abuse or mental disease that may interfere with treatment and follow-up.

          -  Severe malabsorption so that oral treatment are expected to have reduced effect

          -  Mechanical heart valves

          -  Known allergy to apixaban

          -  Active bleeding or severe risk of bleeding so that the risk of bleeding is considered
             a greater danger than the risk of not treating the venous thrombosis

          -  Clinically significant liver disease (e.g., acute hepatitis, chronic active hepatitis,
             or cirrhosis)

          -  Concomitant use of strong cytochrome P-450 3A4 inhibitors (e.g., human
             immunodeficiency virus protease inhibitors or systemic ketoconazole, voriconazole or
             posaconazole) or inducers (e.g., rifampicin, carbamazepine, or phenytoin). Fluconazol
             is allowed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anders EA Dahm, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Akershus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anders EA Dahm, MD, PhD</last_name>
    <phone>+47 93059809</phone>
    <email>aeadahm@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bjørn Tore Gjertsen, PhD, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Jorunn Brekke, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Vestre Viken- Drammen Hospital</name>
      <address>
        <city>Drammen</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alina Carmen Porojnicu, MD</last_name>
      <email>alinacp@vestreviken.no</email>
    </contact>
    <contact_backup>
      <last_name>Anne-Karin Eap</last_name>
      <email>sbeapa@vestreviken.no</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Vestre Viken - Bærum sykehus</name>
      <address>
        <city>Gjettum</city>
        <zip>1346</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hege Frøen, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Hilde Larhammer</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Department of Hematology, Akershus University Hospital</name>
      <address>
        <city>Lørenskog</city>
        <zip>1478</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anders EA Dahm, PhD, MD</last_name>
      <phone>+47 93059809</phone>
      <email>aeadahm@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Marie Jacobsen, MD</last_name>
      <email>e.m.jacobsen@medisin.uio.no</email>
    </contact>
    <contact_backup>
      <last_name>Nina Hviding</last_name>
      <email>ninahv@ous-hf.no</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Østfold Hospital Kalnes</name>
      <address>
        <city>Sarpsborg</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Waleed Ghanima, PhD, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Telemark Hospital- Skien</name>
      <address>
        <city>Skien</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Loyd Frode Ramslien, MD</last_name>
      <email>frode.ramslien@sthf.no</email>
    </contact>
    <contact_backup>
      <last_name>Christine Qvigstad</last_name>
      <email>christine.qvigstad@sthf.no</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Herish Garresori, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petter Quist Paulsen, MD</last_name>
      <email>petter.quist.paulsen@stolav.no</email>
    </contact>
    <contact_backup>
      <last_name>Turid Neverdahl Almvik</last_name>
      <email>Turid.Neverdal.Almvik@stolav.no</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Volda Hospital</name>
      <address>
        <city>Volda</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elin Osvik Velle, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2015</study_first_submitted>
  <study_first_submitted_qc>October 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2015</study_first_posted>
  <last_update_submitted>March 10, 2017</last_update_submitted>
  <last_update_submitted_qc>March 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Akershus</investigator_affiliation>
    <investigator_full_name>Anders Dahm</investigator_full_name>
    <investigator_title>Senior Consultant, Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apixaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

